- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Patent holdings for IPC class A61P 25/28
Total number of patents in this class: 18533
10-year publication summary
|
582
|
656
|
692
|
1124
|
1505
|
1491
|
1639
|
1856
|
1711
|
450
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Mondobiotech Laboratories AG | 311 |
278 |
| F. Hoffmann-La Roche AG | 7958 |
234 |
| The Regents of the University of California | 18943 |
215 |
| Takeda Pharmaceutical Company Limited | 2961 |
170 |
| AstraZeneca AB | 3042 |
135 |
| Hoffmann-La Roche Inc. | 3060 |
129 |
| Janssen Pharmaceutica N.V. | 3839 |
129 |
| Eisai R&D Management Co., Ltd. | 1304 |
121 |
| H. Lundbeck A/S | 1252 |
105 |
| The General Hospital Corporation | 4517 |
102 |
| Novartis AG | 11238 |
100 |
| Eli Lilly and Company | 3645 |
92 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
87 |
| Centre National de La Recherche Scientifique | 9632 |
84 |
| The Johns Hopkins University | 5377 |
80 |
| AC Immune S.A. | 234 |
78 |
| Bristol-myers Squibb Company | 5080 |
74 |
| Ramot at Tel-Aviv University Ltd. | 1370 |
69 |
| Genentech, Inc. | 3742 |
68 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
64 |
| Other owners | 16119 |